Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Novacea Announces Appointment of Daniel M. Bradbury to Board of Directors
PR, Monday November 14, 8:30 am ET

SOUTH SAN FRANCISCO, CA--(MARKET WIRE)--Nov 14, 2005 -- Novacea, Inc. announced today the appointment of Daniel M. Bradbury to the Company's Board of Directors.

Mr. Bradbury is currently Chief Operating Officer of Amylin Pharmaceuticals, Inc. (NasdaqNM:AMLN - News) and a member of the Board of Directors of Illumina, Inc. and Cerexa, Inc. Prior to joining Amylin in 1994, Mr. Bradbury spent eleven years in various international sales and marketing roles with Beecham Pharmaceuticals and SmithKline Beecham Pharmaceuticals. Mr. Bradbury holds a Pharmacy degree from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education and is a member of the Royal Pharmaceutical Society of Great Britain.

"We are delighted to announce that Dan Bradbury has accepted our invitation to join the Novacea Board of Directors," Brad Goodwin, chief executive officer of Novacea said. "With more than 20 years in the biopharmaceutical industry, he brings significant experience, intelligence and passion that will be a tremendous asset to Novacea as we move forward with the development and commercialization of our oncology product pipeline, which includes two Phase 3-ready products."

About Novacea

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea's in-licensed product portfolio features three clinical stage oncology therapeutics. Products ready for Phase 3 studies are DN-101, for the treatment of advanced prostate cancer, and vinorelbine oral, for the treatment of breast or lung cancer. Banoxantrone, or AQ4N, is in a Phase 1 study in advanced malignancies and a Phase 1/2 study in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia. The Company also features a highly-experienced management team and leverages this leadership to ensure that each program fully realizes the benefits of the Company's expertise, creativity and commitment to excellence. For more information, visit www.novacea.com.

http://biz.yahoo.com/iw/051114/0100613.html